Neurology 1999;53:20
© 1999 American Academy of Neurology
Views & Reviews
Matrix metalloproteinases in inflammatory demyelination
Targets for treatment
Bernd C. Kieseier, MD,
Thomas Seifert, MD,
Gavin Giovannoni, FCP and
Hans-Peter Hartung, MD
From the Department of Neurology (Drs. Kieseier, Seifert, and Hartung), Karl-Franzens-Universität, Graz, Austria; and the Neuroimmunology Unit (Dr. Giovannoni), Institute of Neurology, Queens Square, London, UK.
Address correspondence and reprint requests to Dr. Bernd C. Kieseier, Department of Neurology, Karl-Franzens-Universität, Auenbruggerplatz 22, 8036 Graz, Austria.
Article Abstract
Matrix metalloproteinases (MMPs) degrade all protein components of the extracellular matrix. Functionally, they contribute to several different physiologic conditions, such as angiogenesis or bone remodeling, as well as pathologic conditions in humans, such as rheumatoid arthritis and tumor growth. MMPs seem to be important in the pathogenesis of inflammatory demyelinating diseases of the central and peripheral nervous system, especially in MS and in Guillain–Barré syndrome (GBS). Key mechanisms in the genesis of inflammatory demyelination, such as leukocyte recruitment, blood–brain barrier or blood–nerve barrier breakdown, myelin destruction, and release of disease-promoting cytokines, are considered to be MMP-dependent processes. In experimental autoimmune encephalomyelitis, an animal model of MS, and experimental autoimmune neuritis, an animal model of GBS, different synthetic inhibitors targeting MMP activity are able to suppress and even reverse ongoing disease. This evidence points to MMPs as new targets for treatment in inflammatory demyelination.
This article has been cited by other articles:
|
|
|
|
 
A. Goncalves DaSilva and V. W. Yong
Matrix Metalloproteinase-12 Deficiency Worsens Relapsing-Remitting Experimental Autoimmune Encephalomyelitis in Association with Cytokine and Chemokine Dysregulation
Am. J. Pathol.,
March 1, 2009;
174(3):
898 - 909.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
J. E. Harris, J. A. Green, P. T. Elkington, and J. S. Friedland
Monocytes infected with Mycobacterium tuberculosis regulate MAP kinase-dependent astrocyte MMP-9 secretion
J. Leukoc. Biol.,
February 1, 2007;
81(2):
548 - 556.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
B Gran, N Tabibzadeh, A Martin, E S Ventura, J H Ware, G-X Zhang, J L Parr, A R Kennedy, and A M Rostami
The protease inhibitor, Bowman-Birk Inhibitor, suppresses experimental autoimmune encephalomyelitis: a potential oral therapy for multiple sclerosis
Multiple Sclerosis,
November 1, 2006;
12(6):
688 - 697.
[Abstract]
[PDF]
|
|
|
|
|
|
|
E Fainardi, M Castellazzi, T Bellini, M C Manfrinato, E Baldi, I Casetta, E Paolino, E Granieri, and F Dallocchio
Cerebrospinal fluid and serum levels and intrathecal production of active matrix metalloproteinase-9 (MMP-9) as markers of disease activity in patients with multiple sclerosis
Multiple Sclerosis,
June 1, 2006;
12(3):
294 - 301.
[Abstract]
[PDF]
|
|
|
|
|
|
|
K. S. Moshal, U. Sen, N. Tyagi, B. Henderson, M. Steed, A. V. Ovechkin, and S. C. Tyagi
Regulation of homocysteine-induced MMP-9 by ERK1/2 pathway
Am J Physiol Cell Physiol,
March 1, 2006;
290(3):
C883 - C891.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
E. Carmeli, M. Moas, S. Lennon, and S. K Powers
High intensity exercise increases expression of matrix metalloproteinases in fast skeletal muscle fibres
Exp Physiol,
July 1, 2005;
90(4):
613 - 619.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
S. Matias-Roman, B. G. Galvez, L. Genis, M. Yanez-Mo, G. de la Rosa, P. Sanchez-Mateos, F. Sanchez-Madrid, and A. G. Arroyo
Membrane type 1-matrix metalloproteinase is involved in migration of human monocytes and is regulated through their interaction with fibronectin or endothelium
Blood,
May 15, 2005;
105(10):
3956 - 3964.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
B. C. Kieseier, J. J. Archelos, and H.-P. Hartung
Different Effects of Simvastatin and Interferon Beta on the Proteolytic Activity of Matrix Metalloproteinases
Arch Neurol,
June 1, 2004;
61(6):
929 - 932.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
F. Gilli, A. Bertolotto, A. Sala, F. Hoffmann, M. Capobianco, S. Malucchi, T. Glass, L. Kappos, R. L.P. Lindberg, and D. Leppert
Neutralizing antibodies against IFN-{beta} in multiple sclerosis: antagonization of IFN-{beta} mediated suppression of MMPs
Brain,
February 1, 2004;
127(2):
259 - 268.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
G. M. Liuzzi, C. M. Mastroianni, T. Latronico, F. Mengoni, A. Fasano, M. Lichtner, V. Vullo, and P. Riccio
Anti-HIV drugs decrease the expression of matrix metalloproteinases in astrocytes and microglia
Brain,
February 1, 2004;
127(2):
398 - 407.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
S. Jann, M. A. Bramerio, S. Beretta, S. Koch, C. A. Defanti, K. V. Toyka, and C. Sommer
Diagnostic value of sural nerve matrix metalloproteinase-9 in diabetic patients with CIDP
Neurology,
December 9, 2003;
61(11):
1607 - 1610.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
T Seifert, B C Kieseier, S Ropele, S Strasser-Fuchs, F Quehenberger, F Fazekas, and H-P Hartung
TACE mRNA expression in peripheral mononuclear cells precedes new lesions on MRI in multiple sclerosis
Multiple Sclerosis,
December 1, 2002;
8(6):
447 - 451.
[Abstract]
[PDF]
|
|
|
|
|
|
|
G. A. Rosenberg
Matrix Metalloproteinases and Neuroinflammation in Multiple Sclerosis
Neuroscientist,
December 1, 2002;
8(6):
586 - 595.
[Abstract]
[PDF]
|
|
|
|
|
|
|
I. A. Scarisbrick, S. I. Blaber, C. F. Lucchinetti, C. P. Genain, M. Blaber, and M. Rodriguez
Activity of a newly identified serine protease in CNS demyelination
Brain,
June 1, 2002;
125(6):
1283 - 1296.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
V. Brundula, N. B. Rewcastle, L. M. Metz, C. C. Bernard, and V. W. Yong
Targeting leukocyte MMPs and transmigration: Minocycline as a potential therapy for multiple sclerosis
Brain,
June 1, 2002;
125(6):
1297 - 1308.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
C. A. D'Souza, B. Mak, and M. A. Moscarello
The Up-regulation of Stromelysin-1 (MMP-3) in a Spontaneously Demyelinating Transgenic Mouse Precedes Onset of Disease
J. Biol. Chem.,
April 12, 2002;
277(16):
13589 - 13596.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
B. Vaillant, M. G. Chiaramonte, A. W. Cheever, P. D. Soloway, and T. A. Wynn
Regulation of Hepatic Fibrosis and Extracellular Matrix Genes by the Th Response: New Insight into the Role of Tissue Inhibitors of Matrix Metalloproteinases
J. Immunol.,
December 15, 2001;
167(12):
7017 - 7026.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
R. L. P. Lindberg, C. J. A. De Groot, L. Montagne, P. Freitag, P. van der Valk, L. Kappos, and D. Leppert
The expression profile of matrix metalloproteinases (MMPs) and their inhibitors (TIMPs) in lesions and normal appearing white matter of multiple sclerosis
Brain,
September 1, 2001;
124(9):
1743 - 1753.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
C S SETHI, T A BAILEY, P J LUTHERT, and N H V CHONG
Matrix metalloproteinase biology applied to vitreoretinal disorders
Br J Ophthalmol,
June 1, 2000;
84(6):
654 - 666.
[Full Text]
|
|
|
|
|
|
|
C. T. Bever Jr. and G. A. Rosenberg
Matrix metalloproteinases in multiple sclerosis
Neurology,
October 22, 1999;
53(7):
1380 - 1380.
[Full Text]
[PDF]
|
|
|
|
